TEM Latest Headlines

Morgan Stanley Remains a Buy on Tempus AI, Inc. Class A (TEM)

at www.tipranks.com (Fri, 10-Jul 4:07 AM)

Tempus AI’s Real Edge Lies in Its Proprietary Data Layer—What Sets TEM Apart in Life Sciences AI?

Market Chameleon (Wed, 1-Jul 9:21 AM)

Tempus’ Collaboration Creates Unprecedented Molecular Dataset for Rare Angiosarcoma Research

Market Chameleon (Thu, 25-Jun 9:46 AM)

Tempus AI's FDA-Cleared ECG Model Hits Milestone with Multi-Site Validation for Atrial Fibrillation Risk

Market Chameleon (Fri, 12-Jun 11:22 AM)

Tempus to Share AI-Powered Precision Medicine Advancements at Goldman Sachs Global Healthcare Conference

Market Chameleon (Mon, 8-Jun 7:32 AM)

Tempus Launches Open-Source Digital Pathology Consortium With Yale and MSK, Signaling Push Toward Accessible AI-Enabled Medical Data

Market Chameleon (Thu, 4-Jun 11:44 AM)

FDA Approval for Tempus’ Tumor-Only xT CDx Set to Reshape Genomic Profiling in Oncology

Market Chameleon (Fri, 29-May 8:32 AM)

Tempus Sees Record 37 Research Abstracts Accepted for 2026 ASCO Meeting—AI Insights Drive Oncology Progress

Market Chameleon (Tue, 26-May 8:40 AM)

Tempus Expands Clinical Offerings with ArteraAI Prostate Test Integration, Delivering First Digital Pathology Algorithm for Metastatic Prostate Cancer

Market Chameleon (Thu, 21-May 9:00 AM)

Tempus Raises $400 Million in Upsized Convertible Notes Offering with 40% Conversion Premium

Market Chameleon (Fri, 8-May 7:15 AM)

Tempus Collaboration Expands Access to Blood-Based Alzheimer’s Testing for Neurologists

Market Chameleon (Wed, 6-May 8:18 AM)